



The 2nd World Congress on
Controversies in Hematology (COHEM)
Barcelona, Spain • September 6-8, 2012

[Home](#)

[Welcome Note](#)

[Registration](#)

[CME](#)

[General Information](#)

Abstract Submission

Submission deadline is

June 6, 2012

[Click here to submit your abstract](#)

Presentación de resúmenes

La fecha límite de presentación es

6 de junio 2012

[Haga clic aquí para enviar su resumen](#)

A glimpse of the Scientific Program

[▶ See the full program](#)

Un vistazo al Programa Científico

[▶ Ver el programa completo](#)

Session Highlights

Has molecular characterization of cytogenetically normal AML been a major advance in the management of patients?

Moderator: **A.K. Burnett**, UK

Yes: **B. Falini**, Italy

No: **C. Schiffer**, USA

Discussion

Should the new genetic abnormalities and prognostic factors change our management of CLL patients?

Moderator: **R. Foà**, Italy

Yes: **S. Stilgenbauer**, Germany

No: **G. Gaidano**, Italy

Discussion

Is the recommended hematocrit target in polycythemia vera evidence-based?

Moderator: **R. Hehlmann**, Germany

Yes: TBA

No: **T. Barbui**, Italy

Discussion

Is there a role of HDT-ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era?

Moderator: **N. Kröger**, Germany

Yes: **B. Coiffier**, France

No: **A. Hagenbeek**, The Netherlands

Discussion

Is there a role for ASCT for the initial management of high risk DLBCLs?

Moderator: **B. Coiffier**, France

Yes: **C. Haioun**, France

No: **J. Connors**, Canada

Discussion

MM - Cure versus control: Which is the best strategy?

Moderator: **J.F. San-Miguel**, Spain

Cure: **B. Barlogie**, USA

Control: **M. Boccadoro**, Italy

Session Highlights

Has molecular characterization of cytogenetically normal AML been a major advance in the management of patients?

Moderator: **A.K. Burnett**, UK

Yes: **B. Falini**, Italy

No: **C. Schiffer**, USA

Discussion

Should the new genetic abnormalities and prognostic factors change our management of CLL patients?

Moderator: **R. Foà**, Italy

Yes: **S. Stilgenbauer**, Germany

No: **G. Gaidano**, Italy

Discussion

Is the recommended hematocrit target in polycythemia vera evidence-based?

Moderator: **R. Hehlmann**, Germany

Yes: TBA

No: **T. Barbui**, Italy

Discussion

Is there a role of HDT-ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era?

Moderator: **N. Kröger**, Germany

Yes: **B. Coiffier**, France

No: **A. Hagenbeek**, The Netherlands

Discussion

Is there a role for ASCT for the initial management of high risk DLBCLs?

Moderator: **B. Coiffier**, France

Yes: **C. Haioun**, France

No: **J. Connors**, Canada

Discussion

MM - Cure versus control: Which is the best strategy?

Moderator: **J.F. San-Miguel**, Spain

Cure: **B. Barlogie**, USA

Control: **M. Boccadoro**, Italy

Discussion

Preferred 1st line treatment of CML: 2nd generation TKI or optimized Imatinib?

Moderator: **J.L. Steegmann**, Spain
2nd generation TKI: **G. Saglio**, Italy
Optimized Imatinib: **R. Hehlmann**, Germany
Discussion

Discussion

Preferred 1st line treatment of CML: 2nd generation TKI or optimized Imatinib?

Moderator: **J.L. Steegmann**, Spain
2nd generation TKI: **G. Saglio**, Italy
Optimized Imatinib: **R. Hehlmann**, Germany
Discussion

COHEM Faculty

We are honored to welcome the following faculty members: *(Preliminary list)*

- | | |
|---------------------------------------|-----------------------------------|
| E. Angelucci , Italy | E. Montserrat , Spain |
| M. Baccarani , Italy | A. Nagler , Israel |
| T. Barbui , Italy | E. Olavarria , Spain |
| B. Barlogie , USA | A. Palumbo , Italy |
| M. Boccadoro , Italy | A. Piga , Italy |
| A.K. Burnett , UK | E. Rachmilewitz , Israel |
| J. Bussell , USA | A.C. Rawstron , UK |
| Y. Cabantchik , Israel | J.M. Ribera , Spain |
| M.D. Cappellini , Italy | G. Rodgers , USA |
| B. Coiffier , France | G. Saglio , Italy |
| J. Connors , Canada | M.M. Samama , France |
| A. Engert , Germany | J.F. San-Miguel , Spain |
| J. Esteve , Spain | V. Santini , Italy |
| A. Falanga , Italy | M.A. Sanz , Spain |
| B. Falini , Italy | C. Schiffer , USA |
| P. Fenaux , France | S. Sheth , USA |
| R. Foà , Italy | J. Sierra , Spain |
| G. Gaidano , Italy | R. Stasi , UK |
| A. Hagenbeek , The Netherlands | J.L. Steegmann , Spain |
| C. Haioun , France | S. Stilgenbauer , Germany |
| R. Hehlmann , Germany | A. Tefferi , USA |
| D. Hoelzer , Germany | W. Vainchenker , France |
| E. Kimby , Sweden | U. Vitolo , Italy |
| N. Kröger , Germany | J.L. Vives Corrons , Spain |
| F. Lo-Coco , Italy | J. Yahalom , USA |
| J.P. Marie , France | P.L. Zinzani , Italy |

COHEM Ponentes

Nos sentimos honrados en dar la bienvenida a los siguientes ponentes: *(Lista preliminar)*

- | | |
|--|------------------------------------|
| E. Angelucci , Italia | E. Montserrat , España |
| M. Baccarani , Italia | A. Nagler , Israel |
| T. Barbui , Italia | E. Olavarria , España |
| B. Barlogie , EE.UU. | A. Palumbo , Italia |
| M. Boccadoro , Italia | A. Piga , Italia |
| A.K. Burnett , Reino Unido | E. Rachmilewitz , Israel |
| J. Bussell , EE.UU. | A.C. Rawstron , Reino Unido |
| Y. Cabantchik , Israel | J.M. Ribera , España |
| M.D. Cappellini , Italia | G. Rodgers , EE.UU. |
| B. Coiffier , Francia | G. Saglio , Italia |
| J. Connors , Canadá | M.M. Samama , Francia |
| A. Engert , Alemania | J.F. San-Miguel , España |
| J. Esteve , España | V. Santini , Italia |
| A. Falanga , Italia | M.A. Sanz , España |
| B. Falini , Italia | C. Schiffer , EE.UU. |
| P. Fenaux , Francia | S. Sheth , EE.UU. |
| R. Foà , Italia | J. Sierra , Spain |
| G. Gaidano , Italia | R. Stasi , Reino Unido |
| A. Hagenbeek , los Países Bajos | J.L. Steegmann , Spain |
| C. Haioun , Francia | S. Stilgenbauer , Alemania |
| R. Hehlmann , Alemania | A. Tefferi , EE.UU. |
| D. Hoelzer , Alemania | W. Vainchenker , Francia |
| E. Kimby , Suecia | U. Vitolo , Italia |
| N. Kröger , Alemania | J.L. Vives Corrons , España |
| F. Lo-Coco , Italia | J. Yahalom , EE.UU. |
| J.P. Marie , Francia | P.L. Zinzani , Italia |



We would be honored to see you in Barcelona for COHEM 2012!

Será un honor verlos en Barcelona para COHEM 2012!

www.comtecmed.com/cohem

cohem@comtecmed.com

[Contact Us](#)

[Forward to a Colleague](#)

[If you do not want to receive this information in the future, please click to unsubscribe](#)